Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, Lopez-Corral L, Ries I, Bücklein VL, Mohty R, Dreyling M, Baluch A, Shah B, Locke FL, Hess G, Barba P, Bachy E, Lin Y, Subklewe M, Jain MD. Rejeski K, et al. Among authors: subklewe m. Am J Hematol. 2023 Nov;98(11):1699-1710. doi: 10.1002/ajh.27056. Epub 2023 Aug 16. Am J Hematol. 2023. PMID: 37584447
An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA.
Rejeski K, Greco R, Onida F, Sánchez-Ortega I, Bonini C, Sureda A, Gribben JG, Yakoub-Agha I, Subklewe M. Rejeski K, et al. Among authors: subklewe m. Hemasphere. 2023 Apr 27;7(5):e889. doi: 10.1097/HS9.0000000000000889. eCollection 2023 May. Hemasphere. 2023. PMID: 37125259 Free PMC article.
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff PJ, Jeyakumar D, Mao D, Adhikary S, Zhou L, Schuberth PC, Damico Khalid R, Ghobadia A. Shah BD, et al. Among authors: subklewe m. J Immunother Cancer. 2023 Aug;11(8):e007118. doi: 10.1136/jitc-2023-007118. J Immunother Cancer. 2023. PMID: 37648261 Free PMC article.
Recognizing, defining, and managing CAR-T hematologic toxicities.
Rejeski K, Subklewe M, Locke FL. Rejeski K, et al. Among authors: subklewe m. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):198-208. doi: 10.1182/hematology.2023000472. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066881 Review.
Novel immunotherapies in the treatment of AML: is there hope?
Subklewe M, Bücklein V, Sallman D, Daver N. Subklewe M, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):691-701. doi: 10.1182/hematology.2023000455. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066884
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.
Iacoboni G, Sánchez-Salinas MA, Rejeski K, Martín-López AÁ, Kwon M, Navarro V, Jalowiec KA, Hernani R, Reguera-Ortega JL, Gallur L, Blumenberg V, Herrero-García M, Roddie C, Benzaquén A, Delgado-Serrano J, Bailén R, Carpio C, Amat P, López-Corral L, Martín-Martín L, Bastos M, Subklewe M, O'Reilly M, Barba P. Iacoboni G, et al. Among authors: subklewe m. Hemasphere. 2024 Jun 26;8(7):e86. doi: 10.1002/hem3.86. eCollection 2024 Jul. Hemasphere. 2024. PMID: 38948924 Free PMC article.
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.
Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros FX, le Bras F, Bories P, Choquet S, Rubio MT, Iacoboni G, O'Reilly M, Casasnovas RO, Bay JO, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E. Sesques P, et al. Among authors: subklewe m. J Hematol Oncol. 2024 Aug 6;17(1):61. doi: 10.1186/s13045-024-01579-w. J Hematol Oncol. 2024. PMID: 39107847 Free PMC article.
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Ravandi F, Cloos J, Buccisano F, Dillon R, Döhner K, Freeman SD, Hourigan CS, Ossenkoppele GJ, Roboz GJ, Subklewe M, Thiede C, Arnhardt I, Valk PJM, Venditti A, Wei AH, Walter RB, Heuser M. Ravandi F, et al. Among authors: subklewe m. Am J Hematol. 2023 Dec;98(12):1847-1855. doi: 10.1002/ajh.27087. Epub 2023 Sep 6. Am J Hematol. 2023. PMID: 37671649
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Voltin CA, Paccagnella A, Winkelmann M, Heger JM, Casadei B, Beckmann L, Herrmann K, Dekorsy FJ, Kutsch N, Borchmann P, Fanti S, Kunz WG, Subklewe M, Kobe C, Zinzani PL, Stelljes M, Roth KS, Drzezga A, Noppeney R, Rahbar K, Reinhardt HC, von Tresckow B, Seifert R, Albring JC, Blumenberg V, Farolfi A, Flossdorf S, Gödel P, Hanoun C. Voltin CA, et al. Among authors: subklewe m. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1361-1370. doi: 10.1007/s00259-023-06554-0. Epub 2023 Dec 20. Eur J Nucl Med Mol Imaging. 2024. PMID: 38114616 Free PMC article.
Cellular therapy in lymphoma.
Sureda A, Lugtenburg PJ, Kersten MJ, Subklewe M, Spanjaart A, Shah NN, Kerbauy LN, Roddie C, Pennings ERA, Mahuad C, Poon M, Hendricks CL, Kamdar M, Jacobson C. Sureda A, et al. Among authors: subklewe m. Hematol Oncol. 2023 Jun 29. doi: 10.1002/hon.3200. Online ahead of print. Hematol Oncol. 2023. PMID: 37382086 Review.
208 results